Clinical Trials Logo

Filter by:
NCT ID: NCT03636672 Not yet recruiting - Accidental Falls Clinical Trials

Bicycle Simulator Training in Older Adults: A Randomized Controlled Trial

Start date: October 1, 2018
Phase: N/A
Study type: Interventional

A Randomized Control Trial will be conducted with Independent old adults (age 70 years old and older) who willing to participate in the study. They will be randomly allocated to two groups: 1) Stationary bicycle riding that includes perturbation balance training during riding; 2) Stationary bicycle riding that does not includes perturbation balance training during riding. Balance and Gait assessments will be tested before and after 3 months of training (2-3 times a week).

NCT ID: NCT03635398 Not yet recruiting - Procedural Sedation Clinical Trials

Intranasal Midazolam for Pediatric Pre-procedural Sedation and Pre-procedural Anti-anxiety Using sipNose Device - a Randomized Controlled Study

Start date: August 2018
Phase: N/A
Study type: Interventional

A Three-arm, Randomized Controlled Trial for Pediatric Pre-procedural Sedation and Pre-procedural Anti-anxiety: Intranasal Midazolam by SipNose versus MAD Versus oral administration

NCT ID: NCT03634293 Not yet recruiting - Sepsis Clinical Trials

Treatment of Severe Infection With Antihyperlipidemia Drug

Start date: January 2019
Phase: Phase 2/Phase 3
Study type: Interventional

Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors increase LDL receptors by decreasing its degradation. In sepsis the pathogenic substances, endotoxin, lipoteichoic acid, phospholipomannan are the main cause of the ongoing inflammation that causes the severe damage and outcome. these substances are removed from the blood by the LDL receptors. By administering PCSK9 inhibitors to patients with sepsis/septic shock this inflammatory response can be stopped and by doing so improve the patients outcome.

NCT ID: NCT03634150 Not yet recruiting - Clinical trials for Triple Negative Breast Cancer

Safety and Efficacy of IV Nerofeā„¢ Followed by Doxorubicin, In Metastatic Ovarian Cancer and Triple Negative Breast Cancer

Start date: August 20, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1b, open-label, non-randomized, Dose Confirmation study. Subjects will be treated, once a week, with IV doses of Nerofe and low dose (10 mg/m2) Doxorubicin (6-8 hours from one another) in consecutive, 28-day cycles.

NCT ID: NCT03633123 Not yet recruiting - Abdominal Surgery Clinical Trials

Safety and Efficacy of D-PLEX in the Prevention of Post Abdominal Surgery Incisional Infection

Start date: October 2018
Phase: Phase 2
Study type: Interventional

Subjects who are planned to undergo an abdominal (colon) surgery and who will meet the study entry criteria will be randomly divided into 2 groups: for half D-PLEX will be administered concomitantly with the standard of care (SOC). The other half will receive the Standard of Care treatment. Following the surgery subjects will be followed up for additional 5 visits, at least half are in line with the routine practice of surgery Follow-Ups. Visits will include patient safety and wound assessments.

NCT ID: NCT03632564 Not yet recruiting - Clinical trials for Cerebral Arterial Diseases

Modulation of Brain Blood Flow Using Dichoptic Visual and Auditory Stimulation

Start date: October 10, 2018
Phase: N/A
Study type: Interventional

Modulation of brain blood flow using dichoptic Visual and Auditory stimulation using REVIVIEW system will be evaluated.

NCT ID: NCT03629184 Not yet recruiting - Influenza Clinical Trials

Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants With Influenza-Like Symptoms

Start date: November 16, 2018
Phase: Phase 3
Study type: Interventional

This study will evaluate the safety, pharmacokinetics, and efficacy of baloxavir marboxil compared with oseltamivir in a single influenza episode in otherwise healthy pediatric participants (i.e., 1 to <12 years of age) with influenza-like symptoms.

NCT ID: NCT03625518 Not yet recruiting - Clinical trials for Fetal Growth Retardation

Mode of Induction in Fetal Growth Restriction and Its Affects on Fetal and Maternal Outcomes

Start date: September 2018
Phase: Early Phase 1
Study type: Interventional

to compare methods of induction of labor in fetal growth restriction and its effect on maternal and neonatal outcome

NCT ID: NCT03625440 Completed - Waterpipe Smoking Clinical Trials

Acute Effects of Waterpipe Smoking on Cognitive Measures and Cardiorespiratory Parameters

Start date: August 2016
Phase: N/A
Study type: Interventional

Title: Acute effects of waterpipe smoking (WPS) on cognitive measures and cardiorespiratory parameters Objectives: To evaluate the acute effect of one cession of water pipe smoking on: 1. executive functions which evaluated by cognitive tests administered included the digit span subtest Wechsler Adult Intelligence Scale (WAIS)-version III hebrew battery, and the Paced Auditory Serial Addition Test (PASAT) 2. Cardiorespiratory parameters included vital signs, spirometry parameters and lung clearance index (LCI) value 3. serum carboxyhemoglobin, nicotine, and cytokines Design: Prospective study evaluating these parameters before and after 30 minutes of water pipe smoking (WPS). Sample size: 55 participants (35 study group, 20 control group) Participant selection: Adults subjects who regularly smoke water pipe. Intervention: Each subject will undergo evaluation including cognitive tests, Cardiorespiratory parameters, carboxy- hemoglobin levels, nicotine levels, serum cytokines levels. All measurements will be evaluated before and after one cession of 30 minutes water pipe smoking

NCT ID: NCT03622580 Not yet recruiting - Clinical trials for Diabetic Macular Edema

A Study to Evaluate the Efficacy and Safety of RO6867461 in Participants With Diabetic Macular Edema (YOSEMITE)

Start date: September 22, 2018
Phase: Phase 3
Study type: Interventional

This study will evaluate the efficacy, safety, and pharmacokinetics of RO6867461 administered at 8-week intervals or as specified in the protocol following treatment initiation, compared with aflibercept once every 8 weeks (Q8W), in participants with diabetic macular edema (DME).